In our work we analyzed utilisation of antibiotics for systemic use at the Surgical Clinic of the Clinical Hospital Centre - Pristina in Gracanica in 2007. and 2008. Data on antibiotic utilization were delivered on the basis of drug dispensing records from the Central Hospital Pharmacy during the two-years period. Antibiotics were distributed inside the ATC/DDD system in accordance with WHO guidelines. Quantitative antibiotics' utilisation was expressed as number of defined daily doses per 100 patient-days (DDDs/100 PD). Overall use of antibiotics in 2007 was 123.37 DDDs/100 PD, and 125.09 DDDs /100 PD in 2008. Three most utilized antibiotics in 2007. were cefuroxime 24.26 DDDs/100 PD (19.66 % of total antibiotics' use), ceftriaxone 16.65 DDDs/100 PD (13.49 %), and cephalexin 15.78 DDDs/100 PD (12.79 %). In 2008. the most utilized were ceftriaxone 23.23 DDDs/100 PD (18.57 %), cefuroxime 22.53 DDDs/100 PD (18.01 %), and co-trimoxazole 19,55 DDDs/100 PD (15.63 %). Qualitative and quantitative part of the consumed antibiotics was mainly in accordance with the results of similar researches in our country.

Without a knowledge of how drugs are being prescribed and used, it is difficult to suggest measures that would support rational use of drugs and improve prescribing habits in hospitals. In our work we analyzed utilization of antibiotics for systemic use at the Surgical Clinic of the Clinical Hospital Centre - Pristina in Gracanica in 2007. and 2008. on the basis of dispensing records of drugs issued from the Central Pharmacy to the Surgical Clinic for those two years. Antibiotics were distributed according to ATC classification, and antibiotics' utilisation was expressed in number of defined daily doses used per 100 patient-days (DDDs/100 PD). We analized qualitative and quantitative participation of different groups of antibacterials for systemic use. Òhe results of our study were in accordance with available results of similar studies in our country and in the neighbouring environment

Anxiety disorders are very common illnesses that are reported in approximately one third to one quarter of the entire population during the lifetime. Many anxiety disorders are being reported early in life, they have chronic progress, and cause significant difficulties, interfere in daily life activities and create huge economical expenses. It has been evaluated that 46.6 billion dollars out of 147.8 billion dollars overall mental disorders expenses in US is being spent on anxiety disorders, while in European community those expenses exceed 41 billion Euros. In spite of that, pharmacoeconomical aspects of these illnesses so far drawn much less attention than so called large mental illnesses (schizophrenia, depression), and the reason for that is probably that earlier relatively cheep benzodiazepines were dominantly used in treating anxiety disorders. However, in newer times the anti-depressives became the first choice for anxiety disorders, especially those from the group of selective serotonin reuptake inhibitors (SSRI). The increase of anxiety disorders prevalence and changes in modern pharmacotherapy create promising research conditions for starting the studies in area of pharmacoeconomics in the world, and in our country